Ikarian Capital’s Tempest Therapeutics TPST Stock Holding History

Ikarian Capital’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,199	Closed	-$7.41M	–	210
2020 Q1	$7.41M	Buy	+7,199	New	+$10.5M	0.56%	47

Other funds holding TPST

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital's TPST Position: Q1 2025 in Review

Ikarian Capital sold out of Tempest Therapeutics (TPST) in Q1 2025, closing a stake of 8,099 shares — an estimated $87.9K sold.

Ikarian Capital first reported a position in TPST in Q2 2020 and held it in 14 quarters. The position peaked at $1.62M in Q1 2021. 23 funds tracked by Wall St. Rank hold TPST as of Q1 2025.

Ikarian Capital reported no remaining Tempest Therapeutics position as of Q1 2025 after selling out during the quarter.
Ikarian Capital sold 8,099 Tempest Therapeutics shares in Q1 2025, an estimated $87.9K.
Ikarian Capital first reported a position in Tempest Therapeutics in Q2 2020 and held it in 14 quarters.
Ikarian Capital's Tempest Therapeutics position peaked at $1.62M in Q1 2021.
23 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.